Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, Clinical study to compare efficacy and safety of oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India against innovator Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM)

Next Previous
Trial Profile

Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, Clinical study to compare efficacy and safety of oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India against innovator Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPL 2009-0031 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Cadila Pharmaceuticals

Most Recent Events

  • 14 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 13 Mar 2021 Status changed from recruiting to active, no longer recruiting.
  • 10 Jan 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top